PanTher announced today that it received approval from the Human Research Ethics Committee (HREC) to open a Phase 1 clinical trial of PTM-101 in Australia. PTM-101 is being developed for the treatment of pancreatic cancer. The company also announced today the appointment of J. Marc Pipas, MD, as Chief Medical Officer and the establishment of its clinical advisory board. Dr. Pipas, a veteran GI oncologist and clinical trialist who has assisted in the development of multiple oncology agents from Phase 1 trials through commercialization (including ONIVYDE®, which received approval from the FDA for pancreatic cancer and was subsequently sold to Ipsen Pharmaceuticals for $1 billion), will direct PanTher’s clinical development programs.
PanTher Therapeutics Receives Ethics Approval to Initiate Phase 1 Clinical Trial of PTM-101 in Australia